<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02039336</url>
  </required_header>
  <id_info>
    <org_study_id>NL45985.031.13</org_study_id>
    <nct_id>NCT02039336</nct_id>
  </id_info>
  <brief_title>Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC</brief_title>
  <acronym>M13DAP</acronym>
  <official_title>Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Metastatic KRAS Mutation Positive Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II multi-center open-label proof of concept study, consisting of two parts.&#xD;
      Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the&#xD;
      combination regimen of dacomitinib plus PD-0325901 in patients with advanced KRAS mutant&#xD;
      (KRASm) non-small cell lung cancer (NSCLC). Part B is designed to perform a randomized&#xD;
      comparison of the combination of dacomitinib and PD-0325901 versus standard of care therapy&#xD;
      in patients with advanced KRASm NSCLC. It is hypothesized that with this combination strategy&#xD;
      the progression free survival of patients with KRASm NSCLC will be doubled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of dose-limiting toxicities</measure>
    <time_frame>1.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dacomitinib + PD-0325901</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dacomitinib: oral tablets PD-0325901: oral capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacomitinib</intervention_name>
    <arm_group_label>Dacomitinib + PD-0325901</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-0325901</intervention_name>
    <arm_group_label>Dacomitinib + PD-0325901</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Dacomitinib + PD-0325901</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological proof of advanced non-small cell lung cancer&#xD;
&#xD;
          -  Written documentation of KRAS (exon 2, 3 or 4) mutation&#xD;
&#xD;
          -  At least 18 years of age or older&#xD;
&#xD;
          -  Able and willing to give written informed consent&#xD;
&#xD;
          -  WHO performance status of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic or untreated leptomeningeal disease&#xD;
&#xD;
          -  Symptomatic brain metastasis&#xD;
&#xD;
          -  Impairment of gastrointestinal function&#xD;
&#xD;
          -  Uncontrolled infectious disease&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50%&#xD;
&#xD;
          -  Retinal degenerative disease or with history of uveitis, retinal vein occlusion or&#xD;
             retinal detachment&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>f opdam, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FALM Eskens, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Centre Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MPJK Lolkema, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>F Opdam, MD, PhD</last_name>
    <phone>0031205122446</phone>
    <email>f.opdam@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F opdam, MD, PhD</last_name>
      <phone>+31 20 512 2446</phone>
      <email>f.opdam@nki.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <last_update_submitted>August 24, 2018</last_update_submitted>
  <last_update_submitted_qc>August 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

